• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SeaSpine Holdings Corporation filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Other Events, Financial Statements and Exhibits

    1/5/23 7:01:02 AM ET
    $SPNE
    Medical Specialities
    Health Care
    Get the next $SPNE alert in real time by email
    8-K
    SeaSpine Holdings Corp false 0001637761 --12-31 0001637761 2023-01-04 2023-01-04

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 4, 2023

     

     

    SeaSpine Holdings Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36905   47-3251758

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    5770 Armada Drive

    Carlsbad, California

      92008
    (Address of principal executive offices)   (Zip Code)

    760-727-8399

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   SPNE   The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

    Emerging Growth Company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Selection 13(a) of the Exchange Act.  ☐

     

     

     


    Introductory Note

    At 12:01 a.m. Eastern Time on January 5, 2023, SeaSpine Holdings Corporation, a Delaware corporation (“SeaSpine”), and Orthofix Medical, Inc., a Delaware corporation (“Orthofix”), completed their previously announced merger. Pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of October 10, 2022, by and among Orthofix, Orca Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of Orthofix (“Merger Sub”), and SeaSpine, Merger Sub merged with and into SeaSpine (the “Merger”), with SeaSpine continuing as the surviving company and a wholly-owned subsidiary of Orthofix following the transaction.

     

    Item 1.02

    Termination of a Material Definitive Agreement.

    In connection with the Merger, on January 5, 2023, SeaSpine is repaying all of the outstanding obligations in respect of principal, interest and fees under the Amended and Restated Credit Agreement (the “Credit Agreement”), dated July 27, 2018, among SeaSpine and Project Maple Leaf Holdings ULC, as guarantors, and SeaSpine Orthopedics Corporation, SeaSpine, Inc., ISOTIS, Inc., SeaSpine Sales LLC, ISOTIS Orthobiologics, Inc., Theken Spine, LLC, SeaSpine Orthopedics Intermediate Co, Inc., 7D Surgical USA Inc. and 7D Surgical ULC, as borrowers, the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent, and terminated all applicable commitments under the Credit Agreement.

     

    Item 2.01

    Completion of Acquisition or Disposition of Assets.

    The information set forth in the Introductory Note is incorporated herein by reference.

    At the effective time and as a result of the Merger, each share of SeaSpine common stock issued and outstanding immediately prior to the effective time of the Merger was converted into the right to receive 0.4163 fully paid and nonassessable shares of Orthofix common stock (and, if applicable, cash in lieu of fractional shares), or the merger consideration, less any applicable withholding taxes. Also at the effective time of the merger, outstanding restricted stock units to acquire shares of SeaSpine common stock will be assumed by Orthofix and converted into restricted stock units to acquire shares of Orthofix common stock, and outstanding options to purchase shares of SeaSpine common stock will be assumed by Orthofix and converted into options to purchase shares of Orthofix common stock, in each case with necessary adjustments to reflect the exchange ratio.

     

    Item 3.01

    Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    On January 5, 2023, SeaSpine requested that the NASDAQ Stock Market file with the SEC an application on Form 25 to withdraw the SeaSpine common stock from listing on the NASDAQ Global Select Market and terminate the registration of SeaSpine common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition, SeaSpine intends to file with the SEC a certification and notice of termination on Form 15 to terminate the registration of its common stock under the Exchange Act and to suspend its reporting obligations under Section 15(d) of the Exchange Act.

     

    Item 3.03

    Material Modification to the Rights of Security Holders.

    The information set forth in the Introductory Note, Item 2.01, Item 3.01, Item 3.03 and Item 5.03 is incorporated herein by reference.

     

    Item 5.01

    Changes in Control of Registrant.

    As a result of the Merger, a change in control of SeaSpine occurred and the surviving entity of the Merger, SeaSpine, became a wholly-owned subsidiary of Orthofix. Immediately after the closing of, and giving effect to, the Merger, former SeaSpine stockholders own approximately 43.5% of Orthofix on a fully diluted basis and existing Orthofix stockholders own approximately 56.5% of Orthofix on a fully diluted basis.

    The information about the Merger in the Introductory Note and Item 2.01, Item 3.01, Item 3.03 and Item 5.02 of this report is incorporated herein by reference.

     

    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    As a result of the Merger and as of the effective time of the Merger, all of the current directors of the SeaSpine board of directors resigned from their directorships of SeaSpine and any committees of which they were a member. This was not a result of any disagreements between SeaSpine and its directors or officers on any matter relating to SeaSpine’s operations, policies or practices. Each of Keith Valentine, Stuart M. Essig, John B. Henneman III and Shweta Singh Maniar will continue as directors of Orthofix in accordance with the provisions of the Merger Agreement.


    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, the Certificate of Incorporation of SeaSpine was amended and restated in the form of the Certificate of Incorporation that is filed as Exhibit 3.1 hereto and is incorporated herein by reference.

    Pursuant to the terms of the Merger Agreement, the bylaws of Merger Sub as in effect at the effective time of the Merger became the bylaws of SeaSpine. The Amended and Restated Bylaws of SeaSpine are attached as Exhibit 3.2 hereto and incorporated herein by reference.

     

    Item 8.01

    Other Events.

    On January 4, 2023, SeaSpine and Orthofix issued a joint press release announcing the completion of the Merger, effective at 12:01 a.m. Eastern Time. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    No.
      

    Description

      3.1    Amended and Restated Certificate of Incorporation of SeaSpine Holdings Corporation
      3.2    Amended and Restated Bylaws of SeaSpine Holdings Corporation
    99.1    Press Release, dated January 4, 2023
    104    The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        SEASPINE HOLDINGS CORPORATION
    Date: January 5, 2023     By:  

    /s/ Patrick Keran

        Name:   Patrick Keran
        Title:   Senior Vice President, General Counsel
    Get the next $SPNE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SPNE

    DatePrice TargetRatingAnalyst
    11/2/2022$12.00 → $6.75Buy → Hold
    Truist
    4/22/2022$27.00 → $21.00Overweight
    Cantor Fitzgerald
    4/13/2022$20.00Buy
    Truist
    12/21/2021$25.00 → $20.00Buy
    Truist Securities
    10/28/2021$100.00Buy
    Loop Capital
    More analyst ratings

    $SPNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SeaSpine Announces 100th Placement of 7D FLASH™ Navigation System

      CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing fru

      12/27/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221118005106/en/ Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Sen

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

      LEWISVILLE, Texas and CARLSBAD, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Senior Vice President from 2015 through 2022, and as

      11/18/22 7:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities

    $SPNE
    SEC Filings

    See more
    • SEC Form CT ORDER filed by SeaSpine Holdings Corporation

      CT ORDER - SeaSpine Holdings Corp (0001637761) (Filer)

      4/3/23 8:19:25 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by SeaSpine Holdings Corporation

      15-12G - SeaSpine Holdings Corp (0001637761) (Filer)

      1/17/23 4:31:53 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by SeaSpine Holdings Corporation

      EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)

      1/12/23 12:15:22 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:21:07 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:51 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company

      4 - SeaSpine Holdings Corp (0001637761) (Issuer)

      1/9/23 7:20:35 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SeaSpine downgraded by Truist with a new price target

      Truist downgraded SeaSpine from Buy to Hold and set a new price target of $6.75 from $12.00 previously

      11/2/22 6:34:40 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Cantor Fitzgerald resumed coverage on SeaSpine with a new price target

      Cantor Fitzgerald resumed coverage of SeaSpine with a rating of Overweight and set a new price target of $21.00 from $27.00 previously

      4/22/22 9:10:58 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Truist resumed coverage on SeaSpine with a new price target

      Truist resumed coverage of SeaSpine with a rating of Buy and set a new price target of $20.00

      4/13/22 7:17:39 AM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Leadership Updates

    Live Leadership Updates

    See more
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team. Mr. Bostjancic has served as SeaSpine's Chief Financial Officer since 2015. He has been an influentia

      5/3/22 4:04:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine® Announces New Senior Leadership Team Appointments

      CARLSBAD, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the elevation of Dr. Frank Vizesi to Chief Scientific Officer and Shaeffer Bannigan to Vice President, Product Development, Spinal Implants. With his promotion, Mr. Bannigan joins the SeaSpine Senior Leadership Team. Dr. Vizesi joined SeaSpine in 2015 as Director, Research and Development, Orthobiologics. He quickly elevated the approach and defined the vision for delivering best-in-class orthobiologics procedural solutions. Under Dr. Vizesi's leadership, the team deepened

      3/7/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

      CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company's Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent. Ms. Steinway brings over 15 years of experience in the medical device industry, having worked in various strategy, sales and finance functions throughout her career. Currently, she i

      12/14/21 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Financials

    Live finance-specific insights

    See more
    • SeaSpine to Report Third Quarter 2022 Financial Results on November 1, 2022

      CARLSBAD, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. To listen to the live webcast and a replay, please visit the Investors section of the SeaSpine website at: https://www.seaspine.com/. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the des

      10/24/22 7:00:00 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company

      Highly complementary spine and orthopedics portfoliosOne of the industry's broadest biologics and regenerative technology offeringsDifferentiated and synergistic enabling technologiesMeaningful cross-selling revenue synergies and cost savingsFinancial strength to pursue growth investments without need for immediate equity financing Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings Companies to host joint conference call and webcast today at 8:00 a.m. ET LEWISVILLE, Texas and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) --  Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpin

      10/11/22 6:00:00 AM ET
      $OFIX
      $SPNE
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • SeaSpine Reports 19% Revenue Growth and Record Quarterly Revenue for Second Quarter 2022 and Raises Full Year 2022 Revenue Guidance

      CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today second quarter financial results for the three-months ended June 30, 2022. Summary Second Quarter 2022 Financial Results and Recent Highlights Total revenue of $56.3 million, an increase of 19% year-over-yearU.S. revenue of $49.5 million, an increase of 16% year-over-year U.S. spinal implants and enabling technologies revenue of $25.0 million, an increase of 17% year-over-yearU.S. orthobiologics revenue of $24.5 million, an increase of 16% year-over-year International reve

      8/2/22 4:05:00 PM ET
      $SPNE
      Medical Specialities
      Health Care

    $SPNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      1/31/23 1:58:01 PM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/14/22 11:45:59 AM ET
      $SPNE
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)

      SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)

      2/3/22 4:41:28 PM ET
      $SPNE
      Medical Specialities
      Health Care